Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Zhang Financial LLC

Zhang Financial LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,250 shares of the medical research company’s stock after purchasing an additional 300 shares during the quarter. Zhang Financial LLC’s holdings in Amgen were worth $4,914,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AMGN. Strategic Financial Concepts LLC purchased a new position in shares of Amgen during the 2nd quarter valued at approximately $26,000. Hershey Financial Advisers LLC purchased a new stake in Amgen in the 2nd quarter worth $30,000. nVerses Capital LLC acquired a new position in Amgen during the second quarter worth $31,000. Bbjs Financial Advisors LLC acquired a new position in Amgen during the second quarter worth $33,000. Finally, Matrix Trust Co acquired a new position in Amgen during the third quarter worth $36,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Up 0.3 %

Shares of AMGN traded up $1.08 during mid-day trading on Tuesday, reaching $325.70. The stock had a trading volume of 842,171 shares, compared to its average volume of 2,454,336. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85. The business’s fifty day moving average is $326.05 and its 200 day moving average is $311.20. The firm has a market cap of $174.72 billion, a price-to-earnings ratio of 46.37, a P/E/G ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period in the prior year, the company posted $5.00 EPS. On average, sell-side analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.76%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Analyst Ratings Changes

A number of equities analysts have weighed in on AMGN shares. Royal Bank of Canada restated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Truist Financial cut shares of Amgen from a “buy” rating to a “hold” rating and upped their price objective for the stock from $320.00 to $333.00 in a research report on Monday. Oppenheimer restated an “outperform” rating and set a $380.00 price objective on shares of Amgen in a research report on Wednesday, August 7th. TD Cowen upped their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Dbs Bank upgraded shares of Amgen to a “strong-buy” rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $326.95.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.